By Mark T. Fleming, MD
Genetic testing for cancer and targeted drug therapy regimens have changed how multiple cancers, particularly breast cancer, colon cancer, and lung cancers are cared for. More and more, we are finding similar benefits in the diagnosis and treatment of prostate cancer.
High-quality genetic testing now can accurately pinpoint both hereditary and somatic mutations, providing crucial insights into how prostate cancer develops and grows. At the same time, new medications tailored to specific mutations have shown great promise in clinical trials, especially in a metastatic disease that has not responded to standard androgen-deprivation therapy.